Literature DB >> 15982657

Rho and vascular disease.

Barbara E Rolfe1, Nathalie F Worth, Cameron J World, Julie H Campbell, Gordon R Campbell.   

Abstract

The Rho family GTPases are regulatory molecules that link surface receptors to organisation of the actin cytoskeleton and play major roles in fundamental cellular processes. In the vasculature Rho signalling pathways are intimately involved in the regulation of endothelial barrier function, inflammation and transendothelial leukocyte migration, platelet activation, thrombosis and oxidative stress, as well as smooth muscle contraction, migration, proliferation and differentiation, and are thus implicated in many of the changes associated with atherogenesis. Indeed, it is believed that many of the beneficial, non-lipid lowering effects of statins occur as a result of their ability to inhibit Rho protein activation. Conversely, the Rho proteins can have beneficial effects on the vasculature, including the promotion of endothelial repair and the maintenance of SMC differentiation. Further identification of the mechanisms by which these proteins and their effectors act in the vasculature should lead to therapies that specifically target only the adverse effects of Rho signalling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15982657     DOI: 10.1016/j.atherosclerosis.2005.04.023

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  47 in total

1.  Cytoskeleton dynamics: fluctuations within the network.

Authors:  Predrag Bursac; Ben Fabry; Xavier Trepat; Guillaume Lenormand; James P Butler; Ning Wang; Jeffrey J Fredberg; Steven S An
Journal:  Biochem Biophys Res Commun       Date:  2007-02-09       Impact factor: 3.575

Review 2.  RHO GTPase signaling for axon extension: is prenylation important?

Authors:  Filsy Samuel; DiAnna L Hynds
Journal:  Mol Neurobiol       Date:  2010-09-28       Impact factor: 5.590

Review 3.  Smooth muscle cell signal transduction: implications of vascular biology for vascular surgeons.

Authors:  Akihito Muto; Tamara N Fitzgerald; Jose M Pimiento; Stephen P Maloney; Desarom Teso; Jacek J Paszkowiak; Tormod S Westvik; Fabio A Kudo; Toshiya Nishibe; Alan Dardik
Journal:  J Vasc Surg       Date:  2007-06       Impact factor: 4.268

Review 4.  Maintenance of radiation-induced intestinal fibrosis: cellular and molecular features.

Authors:  Valérie Haydont; Marie-Catherine Vozenin-Brotons
Journal:  World J Gastroenterol       Date:  2007-05-21       Impact factor: 5.742

5.  Phosphorylation of claudin-5 and occludin by rho kinase in brain endothelial cells.

Authors:  Masaru Yamamoto; Servio H Ramirez; Shinji Sato; Tomomi Kiyota; Ronald L Cerny; Kozo Kaibuchi; Yuri Persidsky; Tsuneya Ikezu
Journal:  Am J Pathol       Date:  2008-01-10       Impact factor: 4.307

Review 6.  Endothelial cell metabolism in normal and diseased vasculature.

Authors:  Guy Eelen; Pauline de Zeeuw; Michael Simons; Peter Carmeliet
Journal:  Circ Res       Date:  2015-03-27       Impact factor: 17.367

7.  Increased finger skin vasoreactivity and stimulated vasomotion associated with simvastatin therapy in systemic sclerosis hypercholesterolemic patients.

Authors:  Marco Rossi; Laura Bazzichi; Lorenzo Ghiadoni; Ilaria Mencaroni; Ferdinando Franzoni; Stefano Bombardieri
Journal:  Rheumatol Int       Date:  2011-11-06       Impact factor: 2.631

8.  Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity.

Authors:  Rebecca A Stockton; Robert Shenkar; Issam A Awad; Mark H Ginsberg
Journal:  J Exp Med       Date:  2010-03-22       Impact factor: 14.307

Review 9.  Targeting the airway smooth muscle for asthma treatment.

Authors:  Blanca Camoretti-Mercado
Journal:  Transl Res       Date:  2009-07-14       Impact factor: 7.012

10.  Receptor-mediated vascular smooth muscle migration induced by LPA involves p38 mitogen-activated protein kinase pathway activation.

Authors:  Zhi-Bin Zhou; Jian-Ping Niu; Zhi-Jun Zhang
Journal:  Int J Mol Sci       Date:  2009-07-13       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.